Taiwan clears VUNO's AI fundus analysis tool
South Korean firm VUNO has gained the approval of Taiwan's Food and Drug Administration to market its AI fundus analysis software.
VUNO Med-Fundus AI analyses images of the fundus to quickly detect locations of lesions indicative of retinal diseases, including diabetic retinopathy, macular disease and glaucoma.
This latest certification follows Taiwan...
Like many cognitive illnesses, clinical depression isn’t a steady state but a variable condition that has patterns and symptoms that change over time and throughout daily life. So Takeda Pharmaceuticals and Cognition Kit are collaborating on a study to assess whether mobile apps and wearables with continuous monitoring capabilities can be used to glean new insights into major depressive disorder...
UK-based cognitive assessment company Cambridge Cognition has received FDA clearance for Cantab Mobile, the company's iPad-based assessment tool for memory issues in older adults. The app, which already had a CE Mark, received FDA clearance January 13th.
Cantab Mobile is a 10-minute test -- based on the Pairs Associates Learning or PAL test -- administered via a tablet that puts the user through...
